[go: up one dir, main page]

MX2016012788A - Procedimiento para mejorar la solubilidad de proteinas y peptidos usando un enlace del fragmento fc de inmunoglobulina. - Google Patents

Procedimiento para mejorar la solubilidad de proteinas y peptidos usando un enlace del fragmento fc de inmunoglobulina.

Info

Publication number
MX2016012788A
MX2016012788A MX2016012788A MX2016012788A MX2016012788A MX 2016012788 A MX2016012788 A MX 2016012788A MX 2016012788 A MX2016012788 A MX 2016012788A MX 2016012788 A MX2016012788 A MX 2016012788A MX 2016012788 A MX2016012788 A MX 2016012788A
Authority
MX
Mexico
Prior art keywords
immunoglobulin
peptide
fragment
protein
improving solubility
Prior art date
Application number
MX2016012788A
Other languages
English (en)
Other versions
MX387560B (es
Inventor
Dae Jin Kim
Sung Min Bae
Se Chang Kwon
Sung Youb Jung
Jong Soo Lee
Kyu Lim Hyung
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of MX2016012788A publication Critical patent/MX2016012788A/es
Publication of MX387560B publication Critical patent/MX387560B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un procedimiento para mejorar la solubilidad de una proteína o un péptido fisiológicamente activo en comparación con la de una proteína o un péptido fisiológicamente activo que no está conjugado con un fragmento Fc de inmunoglobulina, en el que el procedimiento comprende conjugar la proteína o el péptido fisiológicamente activo con un fragmento Fc de inmunoglobulina; y a una composición para mejorar la solubilidad de una proteína o un péptido fisiológicamente activo, que comprende un fragmento Fc de inmunoglobulina, en el que la composición mejora la solubilidad en comparación con una composición sin un fragmento Fc de inmunoglobulina.
MX2016012788A 2014-03-31 2015-03-31 Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina. MX387560B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20140038032 2014-03-31
PCT/KR2015/003195 WO2015152618A1 (ko) 2014-03-31 2015-03-31 면역글로불린 fc 단편 결합을 이용한 단백질 및 펩타이드의 용해도를 개선시키는 방법

Publications (2)

Publication Number Publication Date
MX2016012788A true MX2016012788A (es) 2016-12-12
MX387560B MX387560B (es) 2025-03-18

Family

ID=54240858

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012788A MX387560B (es) 2014-03-31 2015-03-31 Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina.

Country Status (21)

Country Link
US (2) US20170128589A1 (es)
EP (3) EP4464332A1 (es)
JP (3) JP2017511335A (es)
KR (2) KR102385120B1 (es)
CN (2) CN106488933A (es)
AU (1) AU2015242657B2 (es)
CA (1) CA2944138C (es)
DK (1) DK3127923T3 (es)
EA (1) EA201691795A1 (es)
ES (1) ES2897935T3 (es)
HU (1) HU231358B1 (es)
IL (1) IL248111B (es)
MX (1) MX387560B (es)
MY (1) MY192248A (es)
NO (1) NO20161667A1 (es)
PH (1) PH12016501937A1 (es)
PL (1) PL3127923T3 (es)
SG (2) SG11201608120TA (es)
UA (1) UA124182C2 (es)
WO (1) WO2015152618A1 (es)
ZA (1) ZA201607344B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX387560B (es) * 2014-03-31 2025-03-18 Hanmi Pharmaceutical Co Ltd Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina.
JP6989503B2 (ja) * 2015-12-02 2022-01-05 ハンミ ファーマシューティカル カンパニー リミテッド 脂肪酸誘導体を用いたタンパク質結合体及びその製造方法
US20200230250A1 (en) * 2017-02-03 2020-07-23 Hanmi Pharm. Co., Ltd. Long-acting conjugate of a physiologically active material and use thereof
CN106892978A (zh) * 2017-04-18 2017-06-27 天津世传生物科技有限公司 复合物、蛋白质及二者的制备方法
CN110799194A (zh) 2017-06-20 2020-02-14 马德里加尔制药公司 包含靶向治疗剂的联合疗法
KR102053009B1 (ko) 2018-09-19 2019-12-09 주식회사 바이오앱 돼지 열병 백신용 조성물 및 이의 제조 방법
JP2022508619A (ja) * 2018-10-04 2022-01-19 ラトガーズ， ザ ステイト ユニバーシティ オブ ニュー ジャージー ニューロメジンペプチドを使用して２型サイトカイン媒介性炎症を低減させる方法
WO2020101187A1 (ko) 2018-11-15 2020-05-22 주식회사 바이오앱 식물체에서 바이러스-유사 입자를 발현하는 재조합 벡터 및 이를 이용한 써코바이러스-유사 입자를 포함하는 백신 조성물의 제조방법
KR102250576B1 (ko) 2018-11-15 2021-05-12 주식회사 바이오앱 식물 발현 시스템에서 캡시드 단백질의 발현을 증가시키는 재조합 벡터 및 이를 이용한 바이러스-유사 입자의 제조방법
KR102288367B1 (ko) 2018-11-15 2021-08-11 주식회사 바이오앱 식물체에서 바이러스-유사 입자를 발현하는 재조합 벡터 및 이를 이용한 써코바이러스-유사 입자를 포함하는 백신 조성물의 제조방법
US12441776B2 (en) 2018-11-30 2025-10-14 Eirgen Pharma Ltd. Oxyntomodulin peptide analog formulations
CR20220096A (es) * 2019-09-06 2022-05-11 Novartis Ag Proteínas de fusión terapéuticas
CN116322645A (zh) * 2020-05-22 2023-06-23 韩美药品株式会社 Glp-2的长效缀合物的液体制剂
WO2022080912A1 (ko) * 2020-10-16 2022-04-21 주식회사 아이엠바이오로직스 IgM 영역을 이용한 융합단백질 플랫폼
KR102696265B1 (ko) 2021-02-25 2024-08-21 주식회사 바이오앱 식물 발현 시스템을 이용한 알팔파 모자이크 바이러스 유사 입자 제조 방법 및 이의 활용
KR20240027904A (ko) 2022-08-22 2024-03-05 (주) 에빅스젠 용해도 개선용 펩티드 및 이를 포함하는 용해도 개선 조성물

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
IL155812A0 (en) * 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
MXPA05013565A (es) * 2003-06-12 2006-03-09 Lilly Co Eli Proteinas de fusion analogas al glp-1.
US8263084B2 (en) * 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
RU2352583C2 (ru) * 2003-11-13 2009-04-20 Ханми Фарм. Инд. Ко., Лтд. ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ Fc-ОБЛАСТЬ ИММУНОГЛОБУЛИНА В КАЧЕСТВЕ НОСИТЕЛЯ
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
PL1831252T3 (pl) * 2004-12-22 2009-11-30 Lilly Co Eli Preparaty białka fuzyjnego analogu GLP-1
TWI376234B (en) * 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
KR100755315B1 (ko) 2005-04-11 2007-09-05 엘지전자 주식회사 멀티에어컨 시스템 및 그 동작 방법
GB2427360A (en) * 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
US8658174B2 (en) * 2005-07-27 2014-02-25 Qinghua Wang GLP/1/exendin 4 IgG Fc fusion constructs for treatment of diabetes
KR100824505B1 (ko) 2005-08-16 2008-04-22 한미약품 주식회사 개시 메티오닌 잔기가 제거된 면역글로불린 Ｆｃ 영역의대량 생산방법
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
BRPI0811637B8 (pt) * 2007-05-30 2021-05-25 Genexine Inc proteínas de fusão da imunoglobulina
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
KR20100046185A (ko) * 2007-08-09 2010-05-06 다이이찌 산쿄 가부시키가이샤 데스 도메인 함유 수용체 발현 세포에 아포토시스를 유도하는 이뮤노리포솜
CN101983066B (zh) * 2008-01-30 2016-06-29 印第安那大学科技研究公司 基于酯的胰岛素前药
CN102112493B (zh) * 2008-07-23 2015-04-01 韩美科学株式会社 包含具有三个官能性末端的非肽基聚合物的多肽复合物
EP2376520B1 (en) * 2008-12-19 2014-02-12 Indiana University Research&Technology Corporation Insulin analogs
SG178051A1 (en) * 2009-07-27 2012-03-29 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
WO2011064758A2 (en) * 2009-11-30 2011-06-03 Pfizer Limited Fusion protein
US9867777B2 (en) * 2010-01-19 2018-01-16 Hanmi Science Co., Ltd. Liquid formulations for long-acting G-CSF conjugate
MX2012008453A (es) * 2010-01-19 2012-11-21 Hanmi Science Co Ltd Formulaciones liquiddas para un conjugado de eritropoientina de accion prolongada.
AR081066A1 (es) * 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
AR080993A1 (es) * 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
AR081755A1 (es) * 2010-04-02 2012-10-17 Hanmi Holdings Co Ltd Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo
US9981017B2 (en) * 2010-04-02 2018-05-29 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
KR101337797B1 (ko) * 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
KR101382593B1 (ko) * 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
KR101830344B1 (ko) * 2010-10-26 2018-02-22 한미사이언스 주식회사 피브로넥틴 단편 및 면역글로불린 단편의 융합 단백질 및 이의 용도
KR101303388B1 (ko) * 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
JPWO2012137479A1 (ja) * 2011-04-04 2014-07-28 国立大学法人 東京医科歯科大学 Ｈｉｖ立体構造認識抗体誘導ペプチド
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
DK3878859T5 (da) 2011-06-10 2024-06-10 Hanmi Science Co Ltd Hidtil ukendte oxyntomodulinderivater og farmaceutisk præparat til behandling af fedme omfattende disse
SI2721062T1 (sl) * 2011-06-17 2019-03-29 Hanmi Science Co., Ltd. Konjugat, obsegajoč oksintomodulinski in imunoglobinski fragment, in uporaba le-tega
CN103611163A (zh) * 2011-09-05 2014-03-05 韩美科学株式会社 一种包含干扰素α-缀合物的抗癌用药物组合物
EP3417881A1 (en) * 2011-10-06 2018-12-26 Hanmi Science Co., Ltd. Blood coagulation factor vii and viia derivatives, conjugates and complexes comprising the same, and use thereof
KR20130049671A (ko) * 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
KR102041412B1 (ko) * 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
KR101895047B1 (ko) * 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
AR090281A1 (es) * 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
US10064951B2 (en) * 2012-03-30 2018-09-04 Hanmi Science Co., Ltd. Liquid formulation of highly concentrated long-acting human growth hormone conjugate
CN103509118B (zh) * 2012-06-15 2016-03-23 郭怀祖 胰岛素-Fc融合蛋白
BR112015001052B8 (pt) * 2012-07-19 2022-12-27 Oxford Nanopore Tech Ltd Métodos para distinguir um polinucleotídeo alvo,sensor para distinguir um polinucleotídeo alvo, e, uso de um construto
US10441665B2 (en) * 2012-07-25 2019-10-15 Hanmi Pharm. Co., Ltd. Liquid formulation of long acting insulinotropic peptide conjugate
KR101968344B1 (ko) * 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR092862A1 (es) * 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
AR094821A1 (es) * 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
AR091902A1 (es) * 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
KR101993393B1 (ko) * 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
MY168536A (en) * 2012-11-06 2018-11-12 Hanmi Pharm Ind Co Ltd Liquid formulation of protein conjugate comprising an oxyntomodulin derivative covalently linked to a non-peptidyl polymer to an immunoglobulin fc region
AR096890A1 (es) * 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn
AR096891A1 (es) * 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
HK1225976A1 (en) * 2013-09-27 2017-09-22 Hanmi Pharm. Co., Ltd. Sustained type human growth hormone preparation
MX387560B (es) * 2014-03-31 2025-03-18 Hanmi Pharmaceutical Co Ltd Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina.
TWI684458B (zh) * 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
KR20150140177A (ko) * 2014-06-05 2015-12-15 한미약품 주식회사 단백질 및 펩타이드의 면역원성을 감소시키는 방법
PE20250556A1 (es) * 2015-12-31 2025-02-24 Hanmi Pharmaceutical Co Ltd Agonista triple de receptores de glucagon/glp-1/gip
CA3029518A1 (en) * 2016-06-29 2018-01-04 Hanmi Pharm. Co., Ltd. Glucagon derivative, conjugate thereof, composition comprising same, and therapeutic use thereof

Also Published As

Publication number Publication date
CA2944138A1 (en) 2015-10-08
MY192248A (en) 2022-08-10
CN117065044A (zh) 2023-11-17
PL3127923T3 (pl) 2022-01-31
JP2017511335A (ja) 2017-04-20
JP7322105B2 (ja) 2023-08-07
JP2020040983A (ja) 2020-03-19
EP4464332A1 (en) 2024-11-20
BR112016022844A2 (pt) 2017-10-17
AU2015242657A1 (en) 2016-10-27
EP3127923B1 (en) 2021-08-18
HUP1600621A2 (en) 2017-01-30
CA2944138C (en) 2023-06-20
SG10202107752PA (en) 2021-09-29
EP3889185A3 (en) 2022-01-26
ZA201607344B (en) 2019-04-24
IL248111A0 (en) 2016-11-30
EA201691795A1 (ru) 2017-03-31
DK3127923T3 (da) 2021-11-22
JP2021167352A (ja) 2021-10-21
IL248111B (en) 2022-04-01
KR20220042326A (ko) 2022-04-05
MX387560B (es) 2025-03-18
US20170128589A1 (en) 2017-05-11
KR102385120B1 (ko) 2022-04-12
HU231358B1 (hu) 2023-03-28
US20230220034A1 (en) 2023-07-13
CN106488933A (zh) 2017-03-08
JP7333249B2 (ja) 2023-08-24
WO2015152618A1 (ko) 2015-10-08
SG11201608120TA (en) 2016-11-29
AU2015242657B2 (en) 2020-05-21
EP3127923A4 (en) 2018-04-18
ES2897935T3 (es) 2022-03-03
KR20150113934A (ko) 2015-10-08
PH12016501937A1 (en) 2017-02-06
EP3889185A2 (en) 2021-10-06
EP3127923A1 (en) 2017-02-08
UA124182C2 (uk) 2021-08-04
NZ724926A (en) 2023-11-24
NO20161667A1 (en) 2016-10-19

Similar Documents

Publication Publication Date Title
MX2016012788A (es) Procedimiento para mejorar la solubilidad de proteinas y peptidos usando un enlace del fragmento fc de inmunoglobulina.
CL2022001189A1 (es) Anticuerpos para cd40. (divisional de solicitud n° 2017003427)
AR096687A1 (es) Anticuerpos anti-fcrh5
CL2018001565A1 (es) Inmunoglobulinas conjugadas con lisina c-terminal
CL2018001488A1 (es) Formulación farmacéutica acuosa del anticuerpo anti-pd-l1 avelumab
EA201591465A1 (ru) Специфичные участки для модификации антител для получения иммуноконъюгатов
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
ECSP19029942A (es) Compuestos del péptido tirosina tirosina cíclico con anticuerpo acoplado como moduladores de receptores de neuropéptido y
PE20170665A1 (es) Anticuerpos anti-tau humanizados
PE20161311A1 (es) Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos.
MX386884B (es) Pares de unión para producción de péptidos
DOP2017000031A (es) Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion
MX391989B (es) Conjugados de amatoxina y anticuerpos.
MX2020010262A (es) Manufactura de neurotoxinas de clostridium botulinum recombinantes.
MX2016012124A (es) Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos.
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
PE20150002A1 (es) Anticuerpos anti-fcrn
EA201691251A1 (ru) Цитотоксические пептиды и их конъюгаты
MX2022015250A (es) Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn.
PE20161245A1 (es) Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos
EP3213350A4 (en) Source/drain regrowth for low contact resistance to 2d electron gas in gallium nitride transistors
MX2018002164A (es) Anticerpo anti-epha4.
MX373017B (es) Conjugados de toxina polipeptidica-anticuerpo unidos covalentemente.
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4